Evidence map›Paper›PMID 38117513›Full record

ArticleCancer research2024

CYP2A6 Activity and Cigarette Consumption Interact in Smoking-Related Lung Cancer Susceptibility.

Mulong Du, Junyi Xin, Rui Zheng, Qianyu Yuan, Zhihui Wang, Hongliang Liu, Hanting Liu, Guoshuai Cai, Demetrius Albanes, Stephen Lam and 35 more

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Genetic evidence for POR-mediated ferroptosis in lung cancer prevention: a causal role of granulocyte modulation.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Investigating the role of inflammatory cytokines in mediating the effect of gut microbiota on gastrointestinal cancers: a mendelian randomization study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors at 20 institutions in 16 countries.

Mulong Du *Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0002-2733-6490
Junyi Xin *Department of Bioinformatics, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, P.R. China.ORCID 0000-0001-6677-3936
Rui Zheng *Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, P.R. China.ORCID 0000-0001-7020-3354
Qianyu YuanDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0003-0878-3030
Zhihui WangDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0009-0000-4306-2373
Hongliang LiuDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-7639-0904
Hanting LiuDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, P.R. China.ORCID 0009-0005-2801-2729
Guoshuai CaiDepartment of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina.ORCID 0000-0002-5331-1297
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, NCI, US NIH, Bethesda, Maryland.ORCID 0000-0001-8330-4293
Stephen LamBritish Columbia Cancer Agency, Vancouver, British Columbia, Canada.ORCID 0000-0002-3964-1492
Adonina TardonFaculty of Medicine, University of Oviedo, ISPA and CIBERESP, Oviedo, Spain.ORCID 0000-0001-5150-1209
Chu ChenProgram in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0003-2267-8050
Stig E BojesenDepartment of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0002-4061-4133
Maria Teresa LandiDivision of Cancer Epidemiology and Genetics, NCI, US NIH, Bethesda, Maryland.ORCID 0000-0002-9727-7772
Mattias JohanssonInternational Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0002-3116-5081
Angela RischUniversity of Salzburg and Cancer Cluster Salzburg, Salzburg, Austria.ORCID 0000-0002-8026-5505
Heike BickeböllerDepartment of Genetic Epidemiology, University Medical Center, Georg August University Göttingen, Göttingen, Germany.ORCID 0000-0002-3361-5488
H-Erich WichmannInstitute of Medical Informatics, Biometry and Epidemiology, Ludwig Maximilian University, Munich, Germany.ORCID 0000-0002-1721-3796
Gad RennertClalit National Cancer Control Center at Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel.ORCID 0000-0002-8512-068X
Susanne ArnoldMarkey Cancer Center, University of Kentucky, Lexington, Kentucky.ORCID 0000-0001-6542-9551
Paul BrennanInternational Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0002-0518-8714
John K FieldDepartment of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.ORCID 0000-0003-3951-6365
Sanjay S SheteDepartment of Epidemiology, Division of Cancer Prevention and Population Science, The University of Texas, MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7622-376X
Loïc Le MarchandEpidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.ORCID 0000-0001-5013-980X
Geoffrey LiuPrincess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-2603-7296
Angeline S AndrewNorris Cotton Cancer Center, Geisel School of Medicine, Hanover, New Hampshire.ORCID 0000-0002-3731-5300
Lambertus A KiemeneyRadboud University Medical Center, Nijmegen, the Netherlands.ORCID 0000-0002-2368-1326
Shan ZienolddinyNational Institute of Occupational Health, Oslo, Norway.ORCID 0000-0001-9747-9625
Kjell GrankvistDepartment of Medical Biosciences, Umeå University, Umeå, Sweden.ORCID 0000-0003-4289-2097
Mikael JohanssonDepartment of Radiation Sciences, Umeå University, Umeå, Sweden.ORCID 0000-0003-4182-8923
Neil E CaporasoDivision of Cancer Epidemiology and Genetics, NCI, US NIH, Bethesda, Maryland.ORCID 0000-0001-7562-4609
Angela CoxDepartment of Oncology, University of Sheffield, Sheffield, United Kingdom.ORCID 0000-0002-5138-1099
Yun-Chul HongDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of South Korea.ORCID 0000-0001-9010-7271
Jian-Min YuanUPMC Hillman Cancer Center and Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-4620-3108
Matthew B SchabathDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0003-3241-3216
Melinda C AldrichDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0003-3833-8448
Meilin WangDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, P.R. China.ORCID 0000-0002-4996-958X
Hongbing ShenDepartment of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, P.R. China.ORCID 0000-0002-2581-5906
Feng ChenDepartment of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, P.R. China.ORCID 0000-0002-2699-7190
Zhengdong ZhangDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, P.R. China.ORCID 0000-0002-6730-9251
Rayjean J HungLunenfeld-Tanenbuaum Research Institute, Sinai Health System, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-4486-7496
Christopher I AmosInstitute for Clinical and Translational Research, Baylor Medical College, Houston, Texas.ORCID 0000-0002-8540-7023
Qingyi WeiDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-3845-9445
Philip LazarusDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.ORCID 0000-0002-8686-0874
David C ChristianiDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0002-0301-0242
Harvard University · USCenter for Cancer Research · USCentre international de recherche sur le cancer · FRDuke University · USMinistry of Education · KRNanjing Medical University · CNBC Cancer Agency · CACancer Center of Hawaii · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZACarmel Medical Center · ILDartmouth College · USGerman Cancer Research Center · DEJiangsu Cancer Hospital · CNLunenfeld-Tanenbaum Research Institute · CAMarkey Cancer Center · USMoffitt Cancer Center · USNational Institute of Occupational Health · NONew Generation University College · ETPrincess Margaret Cancer Centre · CARadboud University Nijmegen · NL

Funding

THE CAROTENE AND RETINOL EFFICACY TRIAL (CARET)U01CA063673 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 1994 to 2006
$13.0M
The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2M
Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9M
Prospective studies of cancer etiology and prevention in Shanghai and SingaporeR01CA144034 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2010 to 2014
$7.0M
THE SINGAPORE COHORT STUDY OF DIET AND CANCERR01CA080205 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YUAN, JIAN-MIN · 1999 to 2009
$5.3M
Cancer epidemiology cohorts in Shanghai and Singapore UM1CA182876 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2014 to 2018
$4.3M
Infrastructure Support and Pilot Tissue Collection for the CARET BiorepositoryU01CA167462 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEUHOUSER, MARIAN L · 2018 to 2022
$2.9M
INFRASRUCTURE SUPPORT AND DATA ENHANCEMENTS FOR THE CARET BIOREPOSITORYUM1CA167462 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 2013 to 2017
$2.8M
The UGT2A and 3A metabolizing enzymes and tobacco-related cancer riskR01ES025460 · NIEHS · WASHINGTON STATE UNIVERSITY · PI LAZARUS, PHILIP · 2015 to 2019
$2.8M
NCI NIH HHS R01 CA080205NCI NIH HHS R01 CA144034NCI NIH HHS R35 CA197449NCI NIH HHS U01 CA063673NCI NIH HHS U01 CA167462NCI NIH HHS U01 CA209414NCI NIH HHS UM1 CA167462NCI NIH HHS UM1 CA182876NIEHS NIH HHS R01 ES025460World Health Organization 001
6 · The paper itself

Abstract

Cigarette smoke, containing both nicotine and carcinogens, causes lung cancer. However, not all smokers develop lung cancer, highlighting the importance of the interaction between host susceptibility and environmental exposure in tumorigenesis. Here, we aimed to delineate the interaction between metabolizing ability of tobacco carcinogens and smoking intensity in mediating genetic susceptibility to smoking-related lung tumorigenesis. Single-variant and gene-based associations of 43 tobacco carcinogen-metabolizing genes with lung cancer were analyzed using summary statistics and individual-level genetic data, followed by causal inference of Mendelian randomization, mediation analysis, and structural equation modeling. Cigarette smoke-exposed cell models were used to detect gene expression patterns in relation to specific alleles. Data from the International Lung Cancer Consortium (29,266 cases and 56,450 controls) and UK Biobank (2,155 cases and 376,329 controls) indicated that the genetic variant rs56113850 C>T located in intron 4 of CYP2A6 was significantly associated with decreased lung cancer risk among smokers (OR = 0.88, 95% confidence interval = 0.85-0.91, P = 2.18 × 10-16), which might interact (Pinteraction = 0.028) with and partially be mediated (ORindirect = 0.987) by smoking status. Smoking intensity accounted for 82.3% of the effect of CYP2A6 activity on lung cancer risk but entirely mediated the genetic effect of rs56113850. Mechanistically, the rs56113850 T allele rescued the downregulation of CYP2A6 caused by cigarette smoke exposure, potentially through preferential recruitment of transcription factor helicase-like transcription factor. Together, this study provides additional insights into the interplay between host susceptibility and carcinogen exposure in smoking-related lung tumorigenesis. SIGNIFICANCE: The causal pathway connecting CYP2A6 genetic variability and activity, cigarette consumption, and lung cancer susceptibility in smokers highlights the need for behavior modification interventions based on host susceptibility for cancer prevention.

Indexed as

Lung NeoplasmsTobacco ProductsCarcinogenesisCarcinogensCytochrome P-450 CYP2A6HumansSmokingTranscription FactorsCarcinogensCYP2A6 protein, humanCytochrome P-450 CYP2A6Transcription Factors

Identifiers

PMID38117513
PMCPMC11184964
OpenAlexW4389992996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.